Fortress Biotech, Inc.

FBIO Healthcare Biotechnology

Fortress Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $63.3 million, up 9.69% from fiscal 2024. In the quarter to June 2026, revenue grew 14.0%, EPS fell 116.0%, free cash flow fell 115.4% and total debt fell 35.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.87 0.04 −2.09%
Market cap
$63.7M
P/E
0.6×
Fwd P/E
1.1×
Dividend yield
—
F-score
5/9
Altman Z
−5.47
Beneish M
−0.01
Dividend safety
20/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.94 0.73 0.00 0.00

+8 more quarters

P/S ratio
1.42 1.33 1.61 1.62
P/FCF ratio
1.13 0.74 0.00 0.00
P/Operating CF
(1.64) 0.43 (8.14) (16.50)
P/B ratio
0.47 0.43 1.64 1.55
EV/Sales
(0.89) (1.92) 1.25 1.06
EV/EBITDA
3.00 2.74 0.00 0.00
EV/FCF
(0.71) (1.07) (0.75) (0.63)
Current Ratio
3.96 2.86 2.49 2.19
Net Debt/EBITDA
19.62 47.76 10.18 7.94
Debt/Equity
0.17 0.18 0.84 0.73
Earnings Yield
106.54% 137.63% (2.19%) (12.45%)
Free Cash Flow Yield
88.24% 135.00% (102.44%) (104.20%)
Free Cash Flow per Share
(1.87) 6.46 (0.45) (0.22)
Book value per Share
6.48 6.42 2.23 2.39
Free Cash Flow
(59.36) 203.85 (12.54) (6.11)
EV/EBIT
2.09 2.29 0.00 0.00
Other line items

Show all line items

Columns are period end dates